

BLOOD GLUCOSE TESTING AND DIABETES MANAGEMENT *(SAMPLE COPY, NOT FOR RESALE)*

Trends, Industry Participants, Product Overviews and Market Drivers

TABLE OF CONTENTS

1.	Overview	12	
1.1	Statement of Report	12	
1.2	About This Report	12	
1.3	Scope of the Report	13	
1.4	Methodology	14	
1.5	Executive Summary	15	
2.	Diabetes	20	
2.1	Demographics of Diabetes	21	
2.1.1	Worldwide Diabetes Incidence	21	
2.1.2	Diabetes in the U.S.	25	
2.2	Understanding the Metabolic Conditions Underlying and Associated with Diabetes	30	
2.2.1	Pre-Diabetes Syndrome	31	
2.2.2	Metabolic Syndrome	31	
2.2.3	Progression of Diabetes	31	
2.2.4	Diabetes and Inflammation	32	
2.2.5	Risk Factors and Diabetes	32	
2.2.5.1	Obesity	33	
2.2.5.2	Stress-Induced Hyperglycemia	35	
2.2.6	Complications and Co-Morbidities in Diabetes	36	
2.2.6.1	Preventing Complications and Co-Morbidities in Diabetes	40	
2.2.6.2	Cardiovascular Disease Facts	41	
2.3	Economics of Diabetes	44	
2.3.1	Worldwide Costs of Diabetes	45	
2.3.2	Costs of Diabetes in the U.S.	45	
3.	Market Analysis: Size, Growth, Share and Competitors	50	
3.1	Worldwide Glucose Testing Market	51	
3.1.1	Global Blood Glucose Self-Testing Market	53	
3.1.2	Worldwide Professional Blood Glucose Testing Market	56	
3.1.3	Continuous Glucose Monitoring Markets	57	
3.2	U.S. Market	58	
3.2.1	U.S. Over-the-Counter (OTC) Self-Testing Glucose Market	59	
3.2.2	U.S. Professional Glucose Testing Market	63	
3.3	European Market	64	
3.4	Asian Market	65	
3.4.1	Japanese Market	67	
3.4.2	Chinese Market	68	
3.4.3	Indian Market	71	
3.4.4	Korean Market	73	
3.4.5	Southeast Asian Market	73	
3.4.6	ROW Markets	75	
3.5	Competitive Situation	75	
3.5.1	Key Players in the Self-Testing Market	75	
3.5.2	Analyses of the Self-Testing Market Conditions, Competition and Product Mix	76	
3.5.3	Analyses of the Professional Blood Glucose Monitoring Market	78	
3.6	Market Drivers and Restraints	81	
3.6.1	Market Drivers	81	
3.6.2	Market Restraints	83	
3.7	Market and Product Trends	85	
3.7.1	Market Trends	86	
3.7.2	Technology Trends	86	
3.8	Strategic Recommendations	87	

3.9	Competitive Strategies	90	
3.10	New Opportunities in the Professional Blood Glucose Meter Market	91	
3.11	Adjacent Markets	91	
4.	Glucose Diagnostic and Monitoring Recommendations	92	
4.1	Diagnosis of Diabetes Mellitus	92	
4.2	Tight Glucose Control in Treating Diabetes	95	
4.2.1	Tight Glucose Control Lowers Cardiovascular Complications	96	
4.3	Recommendations for Glucose Control in Diabetic Patients	96	
4.3.1	Recommended Frequency of Blood Glucose Testing	98	
4.3.2	Using Blood Glucose Data to Monitor and Modify Patient Therapy	99	
4.3.3	Testing in Individuals with Type 2 Diabetes	100	
4.3.4	Continuous Glucose Monitoring (CGM)	101	
4.3.5	A1c Testing Recommendations	102	
4.3.6	Blood Glucose Testing for All Hospitalized Patients According to Guidelines by The Endocrine Society	103	
4.4	Hypoglycemia and Treatment	103	
5.	Glucose Testing Technology Platforms and Consumable Products	106	
5.1	Types of Glucose Determination Technologies	106	
5.2	Enzymatic Reactions Used to Determine Glucose Concentrations	107	
5.2.1	Glucose Oxidase (GOX)	107	
5.2.2	Glucose Dehydrogenase (GDH)	108	
5.2.2.1	GDH-NAD (Glucose Dehydrogenase-Nicotinamide Adenine Dinucleotide)	108	
5.2.2.2	GDH-FAD (Glucose Dehydrogenase-Flavin Adenine Dinucleotide)	108	
5.2.2.3	GDH-PQQ (Glucose Dehydrogenase-Pyrroloquinoline Quinone)	108	
5.2.3	Glucose Hexokinase	109	
5.3	Development of Blood Glucose Monitors: A Historical Evaluation	109	
5.3.1	First-Generation Blood Glucose Biosensors	109	
5.3.2	Second-Generation Blood Glucose Biosensors	109	
5.3.3	Third-Generation Blood Glucose Biosensor	110	
5.4	Accuracy and Precision in Glucose Meters	110	
5.4.1	Clinical and Laboratory Standards Institute (CLSI) POCT12-A3	111	
5.4.2	International Organization for Standardization (ISO) 15197:2013	112	
5.4.3	FDA Guidelines for Blood Glucose Testing Systems	112	
5.4.4	Determining Clinical Accuracy Using the Error Grid Analysis (EGA)	115	
5.4.5	Quality Control Criteria	116	
5.4.6	Potential Variables Affecting Glucose Concentrations	117	
5.5	Key Issues for Glucose Testing Devices	117	
5.5.1	Important Elements for Glucose Testing	118	
5.5.2	Key Features to Aid Specific Patient Populations	119	
5.6	Limitations of Existing Glucose Testing	120	
5.6.1	Common User Errors in Glucose Self-Testing	121	
5.6.2	Interfering Substances and Conditions	122	
5.6.2.1	Environmental	122	
5.6.2.2	Physiologic	122	
5.6.2.3	Operational	122	
5.6.2.4	Manufacturing Variations	122	
5.6.2.5	Drugs/Medications	122	
5.6.2.6	Patient Factors	122	
5.6.3	Errors Associated with GDH-PQQ Technology	123	
5.6.4	Optimizing of Point of Care (POC) Blood Glucose Testing	126	
5.7	Potential Areas of Improvement in Blood Glucose Meter Performance	126	
5.8	Blood Glucose Reagent Test Strips	128	
5.9	Comparison of Hand-Held Blood Glucose Meters with Clinical Laboratory Glucose		

Measurements	129	
5.10	Continuous Glucose Monitoring Technology	130
5.10.1	Advantages of Continuous Readings	130
5.10.2	FDA Approval of CGM	130
5.10.3	CGM Functions to Consider	131
5.10.4	New Technologies for CGM	131
5.11	Summary of Technologies Being Explored for Non-Invasive Glucose Monitoring	132
5.11.1	GlucoTrack	132
5.11.2	Non-Invasive Glucose Monitoring Technologies in Development	132
5.11.3	Goals of Non-Invasive Testing	133
5.11.4	Non-Invasive Diabetes Screening Test	134
5.12	A1c Monitoring Technology	134
5.13	Fructosamine Test	136
5.14	Related Reagents and Equipment	137
5.14.1	Lancets	137
5.14.1.1	Types of Lancing Devices	137
5.14.1.2	Market Size	138
5.14.2	Control Solutions and Calibrators	143
5.14.3	Sharps Devices	143
5.14.4	Needle Destruction Devices	144
5.14.5	Urine Strips	144
5.14.6	Ketone Testing	146
6.	Glucose Testing Devices on the Market	148
6.1	Hand-Held Blood Glucose Meters and Strips for Self-Testing	148
6.1.1	LifeScan	151
6.1.2	Roche Diagnostics Corporation	154
6.1.3	Bayer	155
6.1.4	Abbott (MediSense)	157
6.1.5	AgaMatrix, Inc.	159
6.1.6	ARKRAY, Inc.	160
6.1.7	Bionime Corporation	162
6.1.8	BioSense Medical Devices	163
6.1.9	CVS/pharmacy	164
6.1.10	Diabetic Supply of Suncoast	164
6.1.11	Entra Health Systems	164
6.1.12	Fifty50 Pharmacy	165
6.1.13	Fora Care	165
6.1.14	Genesis Health Technologies	166
6.1.15	GlucoCom	166
6.1.16	Infopia	166
6.1.17	Nipro Diagnostics, Inc.	167
6.1.18	Nova Biomedical	168
6.1.19	Oak Tree International Holdings, Inc.	169
6.1.20	Omnis Health	169
6.1.21	Phylaxis	169
6.1.22	Prodigy Diabetes Care, LLC (an Affiliate of Diagnostic Devices, Inc.)	169
6.1.23	Sanofi	170
6.1.24	Target	170
6.1.25	Telcare	171
6.1.26	Tyson Biomedical	171
6.1.27	US Diagnostics, Inc.	171
6.1.28	Walgreens	172
6.1.29	Walmart	172
6.1.30	77 Elektronika Kft.	172

6.1.31	A. Menarini Diagnostics	173	
6.1.32	All Medicus	173	
6.1.33	i-SENS	173	
6.1.34	Apex Biotechnology Corp.	174	
6.1.35	Glucoplus, Inc.	174	
6.1.36	Polymer Technology Systems	174	
6.1.37	Smiths Medical MD, Inc.	174	
6.1.38	TaiDoc Technology Corp.	174	
6.1.39	IN4 Technology Corporation	175	
6.1.40	ACON Laboratories, Inc.	175	
6.1.41	Pepex Biomedical	176	
6.1.42	HMD BioMedical	176	
6.1.43	BTNX	176	
6.1.44	Shasta Technologies and Decision Diagnostics Corporation	176	
6.2	Point of Care Blood Glucose Meters for Professional Use	177	
6.2.1	Abbott	179	
6.2.1.1	Precision Xceed Pro Blood Glucose and Beta-Ketone Monitoring System	179	
6.2.1.2	i-STAT System	179	
6.2.2	ACON Laboratories	180	
6.2.2.1	On Call Platinum Blood Glucose Monitoring System	180	
6.2.3	Alere	180	
6.2.3.1	epoc Blood Analysis System	180	
6.2.3.2	Alere Cholestech LDX System	180	
6.2.4	ARKRAY, Inc.	181	
6.2.4.1	Assure Platinum, Assure Pro, and Assure 4	181	
6.2.5	EKF Diagnostics	181	
6.2.5.1	Biosen Series of Glucose and Lactate Analyzers	181	
6.2.6	HemoCue (a Quest Diagnostics Company)	181	
6.2.6.1	HemoCue Glucose 201 and Glucose 201 DM Systems	181	
6.2.7	HMD BioMedical	182	
6.2.7.1	NS100	182	
6.2.8	Medtronic	182	
6.2.8.1	iPro Continuous Glucose Monitor	182	
6.2.9	Nova Biomedical	182	
6.2.9.1	StatStrip Hospital Glucose Monitoring System	182	
6.2.10	Polymer Technology Systems	182	
6.2.10.1	CardioChek PA Point of Care Device	182	
6.2.11	Roche	183	
6.2.11.1	Accu-Chek Inform II System	183	
6.2.11.2	Accutrend Plus System	183	
6.2.12	Techno Medica Co., Ltd	183	
6.2.12.1	GASTAT-mini	183	
6.2.13	LifeScan	184	
6.3	Clinical Blood Chemistry Analyzers	184	
6.3.1	Abaxis, Inc.	185	
6.3.2	Alere	186	
6.3.3	ARKRAY, Inc.	186	
6.3.4	Beckman Coulter	187	
6.3.5	DiaSys	187	
6.3.6	Instrumentation Laboratory	187	
6.3.7	International Technidyne Corporation (ITC)	188	
6.3.8	Nova Biomedical	188	
6.3.9	Radiometer	189	
6.3.10	Roche	189	
6.3.11	Siemens Healthcare Diagnostics	190	

6.3.12	Span Diagnostics	193
6.3.13	Stanbio Laboratory	193
6.3.14	Techno Medica Co., Ltd	193
6.3.15	YSI Life Sciences	194
6.4	Continuous Glucose Patient Monitoring Systems	194
6.4.1	Medtronic's Continuous Glucose Monitoring Systems (CGMS)	196
6.4.2	DexCom, Inc. G4 Platinum Continuous Glucose Monitoring System	198
6.4.3	FreeStyle Navigator—Abbott's Continuous Glucose Monitor System	199
6.4.4	GlucoDay S Continuous Glucose Monitor	200
6.4.5	Minimally-Invasive Continuous Glucose Monitors in Development	200
6.4.5.1	GlySens, Inc.	200
6.4.5.2	Senseonics (Formerly Sensors for Medicine and Science)	201
6.4.5.3	Ultradian	201
6.4.5.4	GluMetrics	202
6.5	Non-Invasive Glucose Patient Monitoring Systems	202
6.5.1	Cygnus GlucoWatch Biographer	203
6.5.2	AiMedics Pty Ltd.	203
6.5.3	BioTex, Inc.	204
6.5.4	Echo Therapeutics, Inc.	204
6.5.5	EyeSense GmbH	205
6.5.6	Integrity Applications Ltd.	205
6.5.7	LighTouch Medical, Inc.	206
6.5.8	OrSense Ltd.	206
6.5.9	VeraLight, Inc.	206
6.5.10	Xhale, Inc.	207
6.5.11	Lein Applied Diagnostics	207
6.6	A1c Testing	207
6.7	New Product Launches	208
6.7.1	OneTouch Verio Sync Blood Glucose Monitoring System	208
6.7.2	Medtronic's MiniMed 530G with Enlite Sensor Technology	208
6.7.3	Contour Next Link Meter Approved for Use with Medtronic's New MiniMed 530G with Enlite Insulin Pump System	208
6.7.4	Roche's ACCU-CHEK Inform II System Approved by the FDA	208
6.7.5	Abbott Receives CE Mark for FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System	209
6.7.6	Abbott Receives FDA Clearance for FreeStyle Precision Pro Blood Glucose and ² -Ketone Monitoring System	209
6.7.7	LabStyle Innovations' Dario Diabetes Management System	209
6.7.8	BlueStar by WellDoc	209
6.7.9	FDA Approves Bayer's Contour Next EZ	210
6.7.10	Glooko Received its Second 510(k) Clearance for Glucose Monitoring Logbook App	210
6.7.11	Sanofi-Aventis's iBGStar	210
6.7.12	iHealth Glucose Meter Device	211
6.7.13	MyGlucoHealth Diabetes	211
6.7.14	gDrive	211
6.7.15	Enlite Sensor	211
6.7.16	Abbott's FreeStyle InsuLinx	212
6.7.17	Roche Diagnostics launches Accu-Chek Mobile	212
6.7.18	Medtronic Announces Mac Compatibility for CareLink Personal Therapy Management Software for Diabetes	212
6.7.19	Telcare Receives FDA Clearance for its Telcare BGM 3G Blood Glucose Meter	212
6.7.20	OneTouch SelectSimple	213
6.7.21	Shasta GenStrips	213
6.7.22	Medtronic Gains Approval of First Artificial Pancreas Device System, the MiniMed 530G with Enlite	213

6.8	Blood Glucose Meters, CGMs, and Data Management Software in Development	213
6.8.1	Abbott's Flash Glucose Monitoring System	213
6.8.2	Google Announces Plan to Create Contact Lens Glucose Sensors	213
6.8.3	Socrates Health Solutions' Companion Blood Glucose Monitor	214
6.8.4	DexCom and Johnson and Johnson's Animas Working to Develop an Artificial Pancreas	214
6.8.5	Medtronic Enrolling Patients into Trial Testing Third-Generation, Fully-Automated Artificial Pancreas	214
6.8.6	Boston University's Bionic Pancreas Project	214
6.9	Recent Industry Activity	214
6.9.1	Roche Diagnostics Corp. Cutting Jobs in Diabetes Division	214
6.9.2	AgaMatrix and Sanofi-Aventis Enter Global Diabetes Partnership	214
6.9.3	LifeScan, Inc. Terminates Exclusive Supply Agreement with Medtronic MiniMed	215
6.9.4	Kroger Selects WaveSense Diabetes Testing Products	215
6.9.5	Medtronic and Bayer Healthcare Expand International Alliance	215
6.9.6	PositiveID Corporation and IDEAL LIFE Partner to Bring iglucose to Market for Wireless Diabetes Management	215
6.9.7	Roche Diagnostics U.S. and DexCom, Inc. Announce Research and Development Agreement	215
6.9.8	BD and JDRF Collaborating on a Device Using a Single Infusion Catheter for Both CGM and Pump	216
6.9.9	Court Sides with Decision Diagnostics in Patent Infringement Case	216
6.10	M&A Activity	216
6.10.1	Home Diagnostics, Inc. and Nipro Diabetes Systems, Inc. Merge to Become Nipro Diagnostics, Inc.	216
6.10.2	Medtronic, Inc. Acquires New Diabetes Technology from PreciSense AS	216
6.10.3	Geonostics Acquires FlexSite's Consumer Diabetes Tests	217
6.10.4	Radiometer Medical Acquires Hemocue	217
6.10.5	Additional M&A	217
6.10.6	Important Deals in BGM Market	218
7.	Business Trends in Glucose Testing	219
7.1	Drivers of Clinical Glucose Testing	219
7.2	Competition for Professional POC Glucose Testing	219
7.3	Healthcare Cost Controls	219
7.4	Changes in Patient Management	220
7.5	Regionalization of Laboratory Care	220
7.6	Satellite Facilities	221
7.7	Professional Point of Care Testing	221
7.8	Factors Affecting OTC Medical Product Distribution	222
7.9	Drug Stores Critical to the Diabetic Care Category	224
7.10	Drivers of OTC and Self-Testing Markets	224
7.10.1	Brand Loyalty	224
7.11	Cost Elements of Glucose Self-Testing	225
7.12	Costs of Doing Business in Europe	225
7.13	Drivers of European Diagnostics Testing	226
7.14	Cost Containment in Europe	226
7.15	Blood Glucose Self-Testing Insurance Coverage and Reimbursement	226
7.15.1	American OTC Testing and Self-Testing Reimbursement	226
7.15.2	European Reimbursement	227
7.16	Trends in U.S. Laboratory Testing Reimbursement Practices	228
7.17	Reimbursement Challenges	229
7.17.1	New Medicare Part B	230
7.18	Managed Care	230
7.19	Government Regulation of Medical Devices	230
7.19.1	U.S. Regulations	230
7.19.2	E.U. Regulations	233

7.19.3	U.K. Regulations	238	
7.20	Clinical Laboratory Improvement Act (CLIA)		239
7.21	FDA Labeling Requirements	241	
7.22	Legal Liability for Glucose Meters		243
7.23	FDA's Artificial Pancreas Guidance Document		243
8.	Technology Trends	244	
8.1	Improving Today's Over-the-Counter (OTC) Blood Glucose Meters		244
8.2	Biosensor Technology	245	
8.3	Artificial Pancreas	247	
8.4	Telemedicine	248	
8.4.1	Remote Patient Monitoring		251
8.4.1.1	Infopia Eocene System	253	
8.4.1.2	Health Buddy Systems Monitoring Technologies		254
8.4.1.3	GlucoCom Glucose Monitoring System	254	
8.4.1.4	Alere's DayLink Monitor	254	
8.4.1.5	Alere HomeLink Receives FDA Approval for Over-the-Counter Use		255
8.5	Non-Traditional Methods for Sample Collection		255
8.6	Data Management	255	
8.6.1	Medical Device Radiocommunications Service (MedRadio)		255
8.6.2	Connectivity	256	
8.6.3	Advantages of Connectivity		257
8.6.4	Connectivity Platforms		258
8.6.5	DataLink Data Management System		259
8.6.6	RALS-Plus	260	
8.6.7	FDA Required Software Verification		260
8.6.8	Information Management Advances		260
8.6.9	POL Laboratory Data Management		262
8.6.9.1	Electronic Medical Record Systems and Physician Office Laboratory Data Linking Software		263
8.6.9.2	Physician Office Laboratory Data Linking Software and Interface to the Laboratory Information System	264	
8.6.9.3	Technical Problems of Connectivity		265
8.6.9.4	Web-Based Data Interface		265
8.6.10	HIT Competition	265	
9.	Company Profiles	267	
9.1	Abaxis, Inc.	267	
9.2	Abbott Laboratories	268	
9.3	ACON Laboratories	272	
9.4	AgaMatrix	272	
9.5	Alere	272	
9.6	All Medicus Co., Ltd.	273	
9.7	Amedica Biotech	273	
9.8	A. Menarini Diagnostics		273
9.9	Apex Biotechnology Corporation	274	
9.10	ARKRAY	274	
9.11	Bayer	274	
9.12	B. Braun Melsungen	276	
9.13	Beckman Coulter	276	
9.14	Bionime	281	
9.15	Bio-Rad Laboratories, Inc.		281
9.16	BioTex, Inc.	281	
9.17	Calisto Medical, Inc.	281	
9.18	Cambridge Sensors	282	
9.19	DexCom	282	

9.20	Diagnostic Devices/Prodigy Diabetes Care	284
9.21	DiaSys Diagnostic Systems	284
9.22	Echo Therapeutics, Inc.	284
9.23	Entra Health Systems	285
9.24	Fora Care	285
9.25	FIFTY50 Medical, Inc.	285
9.26	Genesis Health Technologies	286
9.27	GenExel-Sein, Inc.	286
9.28	GlucoPlus	286
9.29	GlySens, Inc.	286
9.30	Hainice Medical	286
9.31	HemoCue (a Quest Diagnostics Company)	287
9.32	Home Diagnostics	287
9.33	Infopia Co., Ltd.	287
9.34	IN4 Technology	287
9.35	International Techidyne Corporation (ITC)	287
9.36	Instrumentation Laboratory Company	288
9.37	i-Sense Corporation	288
9.38	Johnson & Johnson	288
9.39	LabStyle Innovations Corporation	290
9.40	Medtronic	290
9.41	Nipro Diagnostics	291
9.42	Nova Biomedical	291
9.43	OrSense Ltd.	292
9.44	Polymer Technology Systems	292
9.45	Prodigy Diabetes Care, LLC (Formerly Diagnostic Devices, Inc.)	292
9.46	Radiometer Medical	293
9.47	Roche Diagnostics	293
9.48	77 Elektronika Kft.	294
9.49	Siemens AG	294
9.50	Smiths Group	295
9.51	TaiDoc Technology	295
9.52	Techno Medica Co., Ltd.	296
9.53	Telcare	296
9.54	U.S. Diagnostics	296
9.55	VeraLight	296
9.56	Ypsomed Holding	297
9.57	YSI Life Sciences	297

INDEX OF FIGURES

Figure 2.1:	Worldwide Diabetes Cases, 2013 and 2035	21
Figure 2.2:	Worldwide Prevalence of Diabetes (%) in Adults (20-79 Years), 2013	22
Figure 2.3:	Annual Number of New Cases of Diagnosed Diabetes Among U.S. Adults Aged 18-79 Years, 1980-2011	25
Figure 2.4:	New Cases of Diabetes Diagnosed in the U.S. Adult Population by Age, 2010	26
Figure 2.5:	Prevalence of Diabetes by Age in the U.S., 2010	26
Figure 2.6:	Diagnosed Diabetes by Age in the U.S., 2013	27
Figure 2.7:	Number of Deaths from Diabetes by Age in the U.S., 2010	29
Figure 2.8:	Number of Diabetes Deaths by Race and Sex in the U.S., 2010	29
Figure 2.9:	Maintenance of Normal Blood Sugar Levels	30
Figure 2.10:	Prevalence of Self-Reported Obesity (BMI \geq 30) Among U.S. Adults, 2012	34
Figure 2.11:	Prevalence of Obesity Among Adults in the U.S., 2009-2010	34
Figure 2.12:	Trends in Obesity Among Children and Adolescents in the U.S., 1988-2010	35

Figure 2.13: Age-Adjusted Percentage of People with Diabetes Aged 35 Years or Older Reporting Heart Disease or Stroke, by Sex, in the U.S., 1997-2011	37
Figure 2.14: Percentage of Adults with Diagnosed Diabetes Reporting Any Mobility Limitation, by Age, in the U.S., 1997-2011	39
Figure 2.15: Number (in Millions) of Adults Aged 18 Years or Older with Diagnosed Diabetes Reporting Visual Impairment, in the U.S., 1997-2011	40
Figure 2.16: Mean Diabetes Healthcare-related Expenditures Per Adult (20-79 Years) with Diabetes (U.S. Dollars), 2013	45
Figure 2.17: How Diabetes Dollars are Spent in the U.S., 2012	47
Figure 3.1: Global Unit Sales of Glucose Testing Reagent Strips, 2013	53
Figure 3.2: Geographic Segments of the Worldwide Glucose Self-Testing Market, 2012 and 2018	54
Figure 3.3: Worldwide Glucose Self-Testing Market by Region, 2018	55
Figure 4.1: Approach to Management of Hypoglycemia	98
Figure 4.2: Glycemic Status—Ranges and Health Implications	105
Figure 5.1: EGA Zones of Clinical Accuracy	116
Figure 5.2: Single-Day Continuous Blood Glucose Data	121
Figure 5.3: Factors that May Adversely Affect Glucose Testing	123
Figure 5.4: Personal Lancet Unit Sales Market Share by Geographic Region, 2013	140
Figure 6.1: Medtronic's Threshold Suspend Feature	197

INDEX OF TABLES

Table 2.1: Regional Estimates of the Number of Diabetes (20-79 Years) in Millions, 2013 and 2035	22
Table 2.2: Countries with the Largest Numbers of Diabetics, 2013	23
Table 2.3: Countries with the Largest Estimated Numbers of Diabetics, 2035	23
Table 2.4: Worldwide Undiagnosed Diabetes in Adults (20-79 Years) by Region and Income Group, 2013	24
Table 2.5: Countries with the Largest Number of Deaths Attributable to Diabetes, 2013	24
Table 2.6: U.S. Population of Diagnosed Diabetics Aged 20-79 Years, 2013	26
Table 2.7: Percentage of U.S. Adults with Diagnosed Diabetes by State, 2010	27
Table 2.8: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S.	36
Table 2.9: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes	38
Table 2.10: Prevalence of Complications Among Patients with Diabetes	38
Table 2.11: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus	38
Table 2.12: Major Causes of End-Stage Renal Disease	39
Table 2.13: Clinical Recommendations for Adults with Diabetes	41
Table 2.14: Laboratory Assessment of Diabetic Vascular Disease	41
Table 2.15: Average Years Gained Free of Diabetes-Related Disease with Intensive Management	41
Table 2.16: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases and Stroke in the U.S., 2010	43
Table 2.17: Cost of Diagnosed Diabetes in the U.S., 2012	46
Table 2.18: Annual Cost of Care of United Healthcare Adult Members with Diabetes, 2009	48
Table 2.19: Healthcare Utilization by Diabetic Patients, 2012	48
Table 3.1: Worldwide Comprehensive Glucose Testing Market (Includes Reagents and Supplies in both the Self-Testing and Professional Markets in \$ Billions), 2012-2018	52
Table 3.2: Total Global Unit Demand for Glucose Testing Reagent Strips, 2012-2018	52
Table 3.3: Global Dollar Sales of Glucose Testing Reagent Strips, 2012-2018	53
Table 3.4: Worldwide Glucose Self-Testing Market Sales (Meters, Strips, and Lancets), 2012-2018	54
Table 3.5: World Market Share of Glucose Self-Testing Marketers, 2013	56
Table 3.6: Global Revenues for Total Professional Blood Glucose Monitoring (Central Laboratory Testing and Hospital POC and POL), 2012-2018	57
Table 3.7: Global Revenues for Professional Point of Care Blood Glucose Monitoring Systems (within Hospitals and Physician's Offices), 2012-2018	57
Table 3.8: Global Revenues for Continuous Glucose Monitoring Systems, 2012-2018	58

Table 3.9: Comprehensive Glucose Testing Market in the U.S. (Includes Reagents and Supplies in the Self-Testing and Professional Markets), 2012-2018	58
Table 3.10: U.S. Blood Glucose Reagent Strip Market (Includes both Self-Testing and Professional Markets), 2012-2018	59
Table 3.11: Market for Glucose Self-Testing in the U.S. (Includes Meters, Strips and Lancets), 2012-2018	59
Table 3.12: Market Share of U.S. Blood Glucose Self-Testing, 2013	60
Table 3.13: U.S. OTC Glucose Self-Testing Market Repeat Retail Replacement Sales Percentages	61
Table 3.14: OTC Blood Glucose Instrument Reagents by Manufacturer Retail	61
Table 3.15: Demographic Characteristics Glucose Self-Testing Kit Buyers	62
Table 3.16: Top Brand Preferences for Glucose Self-Testing Kits	62
Table 3.17: Instances when Patients Prefer Professional's Glucose Testing	62
Table 3.18: Advantages of a Glucose Self-Testing Kit	63
Table 3.19: Disadvantages of Using a Glucose Self-Testing Kit	63
Table 3.20: Popular Shopping Destinations for Buying or Seeking Information on Glucose Self-Testing Kits	63
Table 3.21: Customer Priorities—Glucose Meter Self-Testing Market, 2001, 2006 and 2012	63
Table 3.22: Market for Total Professional Glucose Testing (Central Laboratory and Hospital POC and POL) in the U.S., 2012-2018	64
Table 3.23: U.S. Revenues for Professional POC Blood Glucose Monitoring (Hospital and POL), 2012-2018	64
Table 3.24: European Comprehensive Glucose Testing Market (Includes Reagents and Supplies in the Self-Testing and Professional Markets), 2012-2018	65
Table 3.25: European Market for Glucose Self-Testing (Includes Meters, Strips and Lancets), 2012-2018	65
Table 3.26: Asian Comprehensive Glucose Testing Market (Includes Reagents and Supplies in the Self-Testing and Professional Markets), 2012-2018	66
Table 3.27: Asian Market for Glucose Self-Testing (Includes Meters, Strips and Lancets), 2012-2018	67
Table 3.28: Japanese Comprehensive Glucose Testing Market (Includes Reagents and Supplies in the Self-Testing and Professional Markets), 2012-2018	68
Table 3.29: Japanese Market for Glucose Self-Testing (Includes Meters, Strips and Lancets), 2012-2018	68
Table 3.30: Chinese Comprehensive Glucose Testing Market (Includes Reagents and Supplies in the Self-Testing and Professional Markets), 2012-2018	69
Table 3.31: Chinese Market for Glucose Self-Testing (Includes Meters, Strips and Lancets), 2012-2018	70
Table 3.32: Indian Comprehensive Glucose Testing Market (Includes Reagents and Supplies in the Self-Testing and Professional Markets), 2012-2018	72
Table 3.33: Indian Market for Glucose Self-Testing (Includes Meters, Strips and Lancets), 2012-2018	72
Table 3.34: Number of Clinical Labs in India, 2008	72
Table 3.35: Top Domestic IVD Companies in India	72
Table 3.36: Leading Global IVD Companies in India	73
Table 3.37: Southeast Asian Comprehensive Glucose Testing Market (Includes Reagents and Supplies in the Self-Testing and Professional Markets), 2012-2018	74
Table 3.38: Southeast Asian Market for Glucose Self-Testing (Includes Meters, Strips and Lancets), 2012-2018	74
Table 3.39: Southeast Asian Comprehensive Glucose Testing Market by Country, 2013	74
Table 3.40: Southeast Asian Market for Glucose Self-Testing by Country (Includes Meters, Strips and Lancets), 2013	74
Table 3.41: ROW Comprehensive Glucose Testing Market (Includes Reagents and Supplies in the Self-Testing and Professional Markets), 2012-2018	75
Table 3.42: ROW Market for Glucose Self-Testing (Includes Meters, Strips and Lancets), 2012-2018	75
Table 3.43: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats of the Glucose Point of Care Market	80
Table 3.44: Key Market Drivers for Glucose Testing	82
Table 3.45: Market Drivers for Continuous Glucose Monitoring	82
Table 3.46: Point of Care Glucose Testing Market: Market Drivers Ranked in Order of Impact	82
Table 3.47: Key Market Restraints for Glucose Testing	83
Table 3.48: Market Restraints for Continuous Glucose Monitoring	84

Table 3.49: Point of Care Glucose Testing Market: Market Restraints Ranked in Order of Impact	84
Table 4.1: Criteria for the Diagnosis of Diabetes	92
Table 4.2: Categories of Increased Risk for Diabetes (Pre-Diabetes)	92
Table 4.3: Normal Glucose Values—Fasting State	93
Table 4.4: Criteria for Testing for Diabetes in Asymptomatic Adults	93
Table 4.5: Criteria for Type 2 Diabetes in Asymptomatic Children	94
Table 4.6: Screening for and Diagnosis of Gestational Diabetes Mellitus (GDM)	95
Table 4.7: Glycemic Recommendations for Non-Pregnant Adults with Diabetes	97
Table 4.8: Glycemic Recommendations for Women with Gestational Diabetes	97
Table 4.9: Glycemic Recommendations for Pregnant Women with Pre-Existing Diabetes	97
Table 4.10: Plasma Blood Glucose and A1c Goals for Type 1 Diabetes by Age-Group	97
Table 4.11: Glucose Monitoring Recommendations	99
Table 4.12: Key Issues for SMBG in Insulin-Independent Type 2 Diabetics	100
Table 4.13: A1c Testing Recommendations	102
Table 4.14: Correlation of A1c with Mean Blood Glucose	102
Table 5.1: Analytic Performance Criteria for Glucose Meters	111
Table 5.2: Potential Variables Affecting Glucose Concentrations	117
Table 5.3: Key Features Considered for Glucose Testing Devices	119
Table 5.4: Common User Errors Made While Self-Testing for Blood Glucose	121
Table 5.5: Compatibility of Various Blood Glucose Meters with Icodextrin Peritoneal Dialysis (PD) Solution	124
Table 5.6: Ten Factors Needed to Improve the Performance of Blood Glucose Meters	126
Table 5.7: Features Required For Safe and Effective Meters for Hospital Settings	127
Table 5.8: Key Features Considered for Reagent Test Strips	129
Table 5.9: Differences Between Laboratory Instruments for Glucose Analysis and Hand-Held Blood Glucose Meters	129
Table 5.10: Relationship of A1c to Average Whole Blood and Plasma Glucose Levels	135
Table 5.11: Unit Sales of Homecare Lancets in the U.S., 2012-2017	139
Table 5.12: Unit Sales of Homecare Lancets in the E.U., 2012-2017	139
Table 5.13: Dollar Sales of Homecare Lancets in the U.S., 2012-2017	139
Table 5.14: Dollar Sales of Homecare Lancets in the E.U., 2012-2017	139
Table 5.15: Unit Sales of Homecare Glucose Self-Testing Lancets in the U.S., 2012-2017	140
Table 5.16: Unit Sales of Homecare Glucose Self-Testing Lancets in the E.U., 2012-2017	140
Table 5.17: Competition in the Lancet Market Segment	141
Table 5.18: Limitations of Urine Glucose Monitoring	145
Table 5.19: Advantages of Urine Glucose Monitoring	146
Table 5.20: Blood Ketone Reading Indications	146
Table 6.1: Current Blood Glucose Self-Testing Meters: Sample Size, Test Time, and Other Features	148
Table 6.2: Point of Care Blood Glucose or Blood Gas Meters Marketed for Professional Use	178
Table 6.3: Clinical Blood Chemistry Analyzers with Glucose Assays	185
Table 6.4: Detailed Features of Selected CGM Systems Currently Available	195
Table 6.5: Non-Invasive Glucose Monitoring Systems in Development	203
Table 7.1: POC Procedural Advantages for Hospital Testing	219
Table 7.2: Financial Comparison for Moderate and Waived CLIA Labs	240
Table 8.1: Data Entry and Data Management Features to Include in Future Meters	245
Table 8.2: Leading Companies for Patient Monitoring Products	253
Table 8.3: Customized Reports Must Support CAP and JCAHO Requirements	260

1. Overview

1.1 Statement of Report

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease—sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes—the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes, particularly Type 2 diabetes, among adults across the world. As such, the global market for blood glucose testing products is undergoing a significant transition driven by the advent of new analytical technologies and developments in diabetes treatment. Although the blood glucose testing segment of the *in vitro* diagnostics (IVD) industry is mature, certain segments of the market, such as home testing devices for diabetes management, will exhibit strong growth. What's more, non-invasive testing now represents a major new area for the application of IVD testing. Additionally, direct access testing—or over-the-counter testing, which allows consumers to order tests themselves without visiting a doctor—has emerged as a strong force in the blood glucose testing segment.

The purpose of this TriMark Publications report is to describe the specific market segments for blood glucose testing and diabetes management. This study reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum or plasma or whole-blood glucose concentrations. Moreover, it examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor's offices and at-home care locations.

1.2 About This Report

The main objectives of this analysis are:

- Identifying viable technology drivers through a comprehensive look at platform technologies for glucose testing for diabetes management.
- Understanding the different sectors of glucose testing, such as the home self-testing and the professional glucose testing segments.
- Obtaining a complete understanding of the individual glucose testing platforms from their basic principles to their clinical applications.
- Discovering feasible market opportunities by identifying high-growth applications in different analytical diagnostic areas.
- Focusing on global industry development through an in-depth analysis of the major world markets for glucose measurement technology, including growth forecasts.
- Presenting market figures regarding the current value of blood glucose testing, market projections, market share, key players and sector growth rates.
- Providing a detailed analysis of each of the major device categories, such as blood glucose meters (including non- and minimally-invasive), blood glucose meter test strips, lancets and lancing devices, and urine glucose/metabolite monitoring strips.

This analysis defines the dollar volume of market sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Key questions answered in this examination include:

- How can glucose measuring tools and technologies facilitate improved diabetes patient care?
- What are the main types of glucose testing technologies that are currently available?
- Who are the current key players in this marketplace?
- Which glucose testing market areas have the greatest potential for growth?
- What is the current state of the glucose testing market?
- Which diagnostic companies are investing in new glucose testing technology platform solutions?
- What are the main business strategies adopted by leading glucose testing companies?
- What are the benefits of various glucose testing technology platforms?

Additionally, this study contains:

- Detailed analysis of recent trends in the glucose testing marketplace.
- In-depth profiles of the leading companies with glucose testing tools and technologies.
- Perspectives of the glucose testing industry from leading industry experts.
- Analysis of potential new glucose testing applications in the clinical sector as they pertain to diabetes management.
- Market predictions and trends analysis concerning U.S. expenditures on glucose testing solutions.
- Projections of glucose testing market sizes for U.S., European and Asian markets.
- Projections for future applications of non-invasive tests in glucose testing-related screening.
- Review of commercial glucose testing business strategies such as co-branding.

Analysis includes charts and graphs measuring product growth and trends within the marketplace. Company-specific information—including sales figures, product pipeline status, and research and development (R&D) trends—is provided. Also, this review includes:

- Assessment of glucose testing market drivers and bottlenecks, from medical and scientific community perspectives.
- Discussions on the potential benefits of glucose testing for various sectors of the medical and scientific community, as they relate to diabetes management.
- The current total market size and future growth of the glucose testing market and analysis of the current size and growth of individual segments.
- Current and forecasted market shares by companies.
- Discussions on profit and business opportunities by segments.
- Strategic recommendations for near-term business opportunities.
- Analysis of the current commercial uses of the glucose testing market by diabetes management.

The following questions will also be addressed in this report:

- What are the near-term business opportunities in the glucose testing market?
- What are the current and forecasted glucose testing market sizes in the U.S., European Union (E.U.) and Japan, as well as in other emerging markets such as India and China?
- What are the business models currently used by companies in the glucose testing market?
- How will manufacturers, researchers, physicians and patients influence diabetes management?
- What are the drivers and bottlenecks influencing the glucose testing market?
- What are the barriers to entry for the glucose testing market?
- What are the key technologies used in glucose testing?
- Who holds the proprietary rights to the glucose testing market technology platforms?
- How is this technology currently being applied and utilized?
- In the U.S. and the E.U., what regulatory processes apply to glucose testing technologies?
- How will new glucose testing technologies change diagnostic screening/testing paradigms and reduce diagnostic false negatives and decrease costs of patient care?
- How will new glucose testing technologies reduce healthcare expenditures and affect R&D spending?

1.3 Scope of the Report

This analysis emphasizes companies that are actively developing and marketing instrumentation, reagents and supplies for performing glucose tests. The world's three largest analytical markets, the U.S., Japan and Europe, are the primary focus here. Specific attention is paid to the clinical market segment and, separately, to the instruments, reagents and supplies marketed by major companies for the home self-testing market for diabetes management. Market size, growth rates and market components for instruments, reagents, controls and consumables used in this area are also analyzed. Activity and trends in research, including patterns of information processing in array testing

instruments, are addressed. Also discussed are trends that have stimulated this market, the numbers of institutions that use glucose testing and the factors that influence purchasing.

This report surveys all companies known to be marketing, manufacturing or developing instruments and reagents for the glucose testing market, for each of the major market segments of professional glucose testing, and self-monitoring of blood glucose. There are also sections on the companies' histories, product lines, business and marketing analyses, and a subjective commentary on the key companies' market positions. In-depth analysis of diabetes management and glucose self-testing can be found in other TriMark Publications reports at www.trimarkpublications.com, such as TriMark's *Diabetes, Metabolic Syndrome and Cardiovascular Disease* and *World Glucose Self-Testing Markets*.

1.4 Methodology

The author of this report is a Ph.D. in biochemistry from the University of Minnesota, with many decades of experience in science writing and as a medical industry analyst. He has over 30 years of experience in laboratory testing, and instrument and reagent development technology, as well as extensive experience in senior level positions in biotech and medical service companies. The senior editor of this report holds a Master's degree in immunology, and has substantial experience in science writing and as a medical industry analyst. She also has many years of laboratory experience investigating cancer immunotherapies, has conducted laboratory testing, and instrument and reagent development for biotech companies. The senior advisor is a Ph.D. in biochemistry and a Professor of pathology at Tufts University School of Medicine and Medical Director, Clinical Chemistry for Baystate Health in Springfield, Massachusetts. He is an internationally-renowned expert in the areas of laboratory automation, quality control informatics, therapeutic drug monitoring, clinical toxicology and pre-analytical variation.

Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additionally, sources of information include the non-governmental organizations (NGOs) such as the World Health Organization (WHO), governmental entities like the U.S. Department of Health and Human Services (HHS), and U.S. federal agencies such as National Institutes of Health (NIH), Food and Drug Administration (FDA) and the Centers of Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as Sector Snapshots that it publishes annually. TriMark extracts relevant data and analytics from its research as part of this data collection.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

TriMark Publications Report, Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report in TriMark Publications includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available data and proprietary databases.
- Formulating a study outline with the assigned writer, including important items, as follows:
 - Market and product segment grouping, and evaluating their relative significance.
 - Key competitors' evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
 - End-user research to evaluate analytical significance in market estimation.
 - Supply chain research and analysis to identify any factors affecting the market.
 - New technology platforms and cutting-edge applications.
- Identifying the key technology and market trends that drive or affect these markets.
- Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
- Completing a confirmatory primary research assessment of the report's findings with the assistance of expert panel partners from the industry being analyzed.

1.5 Executive Summary

Advances in diabetes treatment have revolutionized the blood glucose testing market. Direct access testing—which allows consumers to order and conduct tests themselves without visiting a doctor—has emerged as a strong force in the blood glucose testing segment. Indeed, there's an increasing range of test devices now available to consumers to perform self-testing. Moreover, automation is now a well-established trend in the central clinical laboratory, driven primarily by efforts to reduce costs, and a continuing shortage of qualified technologists and technicians. Information management, including Internet-based reporting and consultation—as well as remote data acquisition and result-reporting for point of care (POC) glucose testing—is becoming a more important element of many suppliers' product offerings. The analysis and reporting of data from blood glucose tests is another area that will become increasingly important in the future. The risk for the later development of microvascular disease makes it important to identify patients with Type 2 diabetes (sometimes referred to as adult onset diabetes). Demonstration of unequivocal hyperglycemia (plasma glucose >200 mg/dL [11.1 mmol/L]) two hours or more after a mixed meal is considered diagnostic for diabetes mellitus according to [REDACTED]. Moreover, HbA1C levels are now accepted as an indicator of diabetes. As such, frequent monitoring of blood glucose levels facilitates control of diabetes.

Worldwide, there are about [REDACTED] diabetics according to [REDACTED]. Due to rising rates of obesity and increased lifespan, the prevalence of diabetes is on the rise. By [REDACTED], the global incidence of diabetes is expected to increase more than [REDACTED]%, afflicting [REDACTED] people worldwide. Despite this large patient population, the IDF estimates that, even now, only [REDACTED]% of Type 2 diabetics have been diagnosed in the worldwide population. In light of this staggering worldwide prevalence of diabetes mellitus, there is increasing demand for effective monitoring of blood glucose and tight glucose control to delay disease progression, prevent diabetic complications and improve the quality of life for patients. Approximately [REDACTED] deaths were attributable to health complications arising from diabetes in [REDACTED], and the number of deaths continues to increase each year. The number of worldwide deaths due to diabetes increased [REDACTED]% from [REDACTED] to [REDACTED]. Nearly half of all deaths due to diabetes occurred in people under the age of 60.

The ten countries containing the largest population of diabetic patients are: China, India, U.S., Brazil, Russian Federation, Mexico, Indonesia, Germany, Egypt and Japan. There are currently an estimated [REDACTED] people in the U.S. afflicted with diabetes (men [REDACTED]%, women [REDACTED]%, non-Hispanic black [REDACTED]%, non-Hispanic whites [REDACTED]%). An estimated [REDACTED] new cases of diabetes are diagnosed each year in the U.S.

The sector for glucose testing devices is large, but very competitive and overpopulated. The comprehensive blood glucose testing market includes devices for use in physician office laboratory (POL), professional POCT in a variety of healthcare settings, self-testing and central labs. Worldwide, more than 80 companies market blood glucose monitors. In addition, there are a few large and fully diverse diagnostic companies that dominate the glucose testing sector. Primarily, the increasing number of diagnosed diabetic patients who closely monitor their own blood glucose values drives the blood glucose testing market, especially in the emerging markets. However, pricing pressures have reduced overall revenue growth to single digits. Although still in development, the non-invasive testing sector continues to attract more entrants to the industry and is heavily technology driven.

There are two key market segments for glucose testing: self-testing and professional testing. Self-testing glucose meters and strips were worth \$ [REDACTED] worldwide in [REDACTED] and are expected to grow to over \$ [REDACTED] by [REDACTED]. The U.S. self-testing diabetes diagnostic market for glucose monitoring devices was a \$ [REDACTED] market in [REDACTED]. The global professional glucose testing market, which includes POC in healthcare settings and central lab tests but excludes self-testing, was worth \$ [REDACTED] in [REDACTED]. The diabetic test strip market is very large and growing. Sales of blood glucose testing strips led the U.S. industry, with manufacturers' sales of over \$ [REDACTED] in [REDACTED]. The hand-held glucose monitor market is dominated by the four large international companies: Roche, Johnson & Johnson (LifeScan), Bayer and Abbott.

There were approximately [REDACTED] Europeans diagnosed with diabetes mellitus in [REDACTED] according to [REDACTED]. Left untreated, the number of diabetics in Western Europe is expected to reach [REDACTED] by [REDACTED]. Of this, [REDACTED] % suffer from Type 1 diabetes. There are about [REDACTED] % of European diabetic patients practicing self-glucose monitoring. The total European glucose monitoring market, which includes self-testing and professional glucose testing, reached \$ [REDACTED] in [REDACTED]. Growing at a compounded annual growth rate (CAGR) of [REDACTED] %, the comprehensive European glucose monitoring market is estimated to be valued at \$ [REDACTED] by [REDACTED].

According to [REDACTED], the Southeast Asia and Western Pacific region is believed to have had at least [REDACTED] diabetics in [REDACTED], and by [REDACTED] the number of diabetes patients is expected to reach [REDACTED]. The rising incidence of diabetes has prompted a flourishing market, not only for the pharmaceutical manufacturers but also for companies producing diabetes monitoring devices and drug delivery systems. Japan, with an aging population and declining birthrates, is the most advanced country for medical care and diagnostic testing in the Asian region. In addition, as the two most populous countries in the world, China and India are hot spots for manufacturers of glucose meters.

According to industry experts, the market for blood glucose test strips, which comprise [REDACTED] % of the U.S. blood glucose testing market, was approximately \$ [REDACTED] in [REDACTED] and is expected to grow to \$ [REDACTED] in [REDACTED], at a CAGR of [REDACTED] %. Estimates place the global market for blood glucose strips at approximately \$ [REDACTED], growing at [REDACTED] % per annum through [REDACTED]. The total home care lancet demand in the U.S. and E.U. was about [REDACTED] units and [REDACTED] units, respectively, in [REDACTED].

Clinical chemistry analyzers are positioned in hospitals, reference labs, independent labs, regional labs, and doctor's offices. They range from the ultra-large to the small, based on their throughput (and price). Glucose testing occurs in virtually every chemistry profile put through these analyzers. The volume of glucose testing in these settings dwarfs the out-sized self-testing market in terms of numbers of tests. TriMark estimates more than [REDACTED] glucose tests are performed in the U.S. on these analyzers. However, the price per test is very low, on the order of ten or [REDACTED] per test, due to the efficiency of these highly engineered instruments.

The explosion of glucose monitoring devices on the market has given consumers an unprecedented choice of instruments and reagents to monitor blood glucose levels. It has also given manufacturers and developers of new technology a cohort of customers who are used to changing devices and are looking for new technologies. Underlying all of this is the classic "razor and razor blade" marketing model. Each manufacturer makes a different test strip, and they are not interchangeable from one monitor to another. Some even make a different strip for each individual monitor type. The reagents substantially drive sales, as costs and ease of use are large factors in customer choice.

Co-branding is one of the strategies that seem to offer smaller companies successful entry into the crowded glucose testing market and provides good market share. Co-branding is valuable to a device manufacturer in a number of ways:

- Manufacturers launch a co-branding program with a product line that represents the latest technology and the highest of quality standards.
- Co-branding sets the stage for a number of initiatives for other chronic disease products and services in the direct-to-consumer needs category.
- It raises the profile of smaller, less well-known companies. It leverages the marketing power of the pharmacy or retail co-branding partner for the small device manufacturer.

Additional recommendations include:

- Focusing diagnostic development on the significant and largely untapped global market that exists by creating more effective and affordable tests to manage diabetes.
- Developing better ways of monitoring glucose levels *in vivo* with continuous monitoring techniques.
- Moving to continuous glucose monitoring that may be partnered with insulin pumps to enable automated disease management using a closed loop system.
- Developing more accurate and reliable monitoring devices to take advantage of the increasing numbers of nursing home and other professional healthcare settings that are utilizing hand-held blood glucose monitoring products.